Regulation Of Nuclear Factor-kappa B Activity

核因子-κ B 活性的调节

基本信息

  • 批准号:
    7132351
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

IkappaB kinase (IKK) catalytic subunits play a key role in cytokine-mediated nuclear factor (NF)-kappaB signaling, and a loss of NF-kB function appears to inhibit inflammation and oncogenesis. Manumycin A, a natural epoxyquinoid compound, is a potent and selective farnesyltransferase inhibitor with antitumor activity. Our recent findings indicate that treatment with manumycin A resulted in a rapid, selective and potent inhibition of TNF alpha-stimulated IKK activity in a number of cell lines and a primary culture of rat hepatocytes. Unexpectedly, other classes of farnesyltransferase inhibitors had no inhibitory effect. To identify the molecular mechanisms of manumycin A action, we transfected human HepG2 hepatoma cell line with IKKalpha and IKKbeta constructs and demonstrated direct inhibition of IKK activity with concomittant formation of stable homotypic IKKbeta dimers in the presence of manumycin A. A number of Cys-> Ala point mutants of IKKbeta were generated to investigate the possibility that IKKbeta covalent dimerization results from nucleophilic attack on the epoquinoid core of manumycin A. Cells expressing IKKbeta mutated in the activation loop at Cys-179 exhibited similar dimer formation, whereas double substitution of Cys-662 and ?716 conferred protection against homotypic dimerization by manumycin A. IKK interaction with the adaptor protein IKKgamma/NEMO was also disrupted in manumycin A-treated cells. Thus, manumycin A plays important regulatory function in IKK signaling through pathways distinct from its role as farnesylation inhibitor. We are currently using an in vivo approach to investigate the hypothesis that manumycin A affects the activation of IKKbeta, a major contributor to inflammation-induced insulin resistance. Injection of various concentrations of manumycin A has been carried out in murine B16F10 melanoma implanted s.c. in the back of several mice. The tumor masses were excised, weighted and are currently being processed for Western blot, in vitro IKK activity and EMSA (NF-kappaB) studies. It is anticipated that our results will demonstrate that IKKbeta is a direct target of manumycin A in vivo. Future plans include the study of the effect of manumycin A in the regulation of insulin responsiveness in physiological and pathophysiological pro-inflammatory states such as diet-induced obesity and aging.
IkappaB激酶(IKK)催化亚基在细胞因子介导的核因子(NF)-kappaB信号传导中起关键作用,NF- kb功能的丧失似乎可以抑制炎症和肿瘤的发生。马霉素A是一种天然的环氧醌类化合物,是一种有效的选择性法尼基转移酶抑制剂,具有抗肿瘤活性。我们最近的研究结果表明,在许多细胞系和原代培养的大鼠肝细胞中,马霉素A治疗导致了TNF α刺激的IKK活性的快速、选择性和有效的抑制。出乎意料的是,其他种类的法尼基转移酶抑制剂没有抑制作用。为了确定马霉素A作用的分子机制,我们用IKKalpha和ikkβ构建体转染人HepG2肝癌细胞系,发现在马霉素A存在的情况下,ikkβ活性直接受到抑制,同时形成稳定的同型ikkβ二聚体。为了研究ikkβ的一些Cys-> α点突变体是由对马霉素A的环氧类核心的亲核攻击导致ikkβ共价二聚体的可能性,表达ikkβ的细胞在Cys-179激活环中发生突变Cys-662和?在马霉素a处理的细胞中,IKK与衔接蛋白IKKgamma/NEMO的相互作用也被破坏。因此,马霉素A通过不同于法尼化抑制剂的途径在IKK信号传导中发挥重要的调节作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHEL BERNIER其他文献

MICHEL BERNIER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHEL BERNIER', 18)}}的其他基金

INSULIN RECEPTOR THIOL REACTIVITY AND INSULIN SIGNALING
胰岛素受体硫醇反应性和胰岛素信号传导
  • 批准号:
    6288766
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
ANTIAPOPTOTIC FUNCTION OF THE INSULIN RECEPTOR
胰岛素受体的抗凋亡功能
  • 批准号:
    6288768
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Effects of pyrrolidine dithiocarbamate on the function of mTOR complex 1 and 2
吡咯烷二硫代氨基甲酸酯对 mTOR 复合物 1 和 2 功能的影响
  • 批准号:
    8335949
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Regulation Of Nuclear Factor-kappa B Activity
核因子-κ B 活性的调节
  • 批准号:
    7324970
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Regulation Of Nuclear Factor-kappa B Activity
核因子-κ B 活性的调节
  • 批准号:
    7732342
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Regulated expression of the orphan nuclear estrogen-related receptor alpha
孤儿核雌激素相关受体α的调节表达
  • 批准号:
    8156794
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Inhibition of IL-6 signaling by a mechanism involving mTOR inactivation
通过 mTOR 失活机制抑制 IL-6 信号传导
  • 批准号:
    8148336
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
INTERACTION BETWEEN THE INSULIN RECEPTOR AND TRAP
胰岛素受体和陷阱之间的相互作用
  • 批准号:
    6431483
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Insulin Regulation Of Nuclear Factor-kappa B Activity
胰岛素对核因子-κ B 活性的调节
  • 批准号:
    6663585
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Insulin Regulation of Nuclear Factor Kappa B Activity
胰岛素对核因子 Kappa B 活性的调节
  • 批准号:
    6508460
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
  • 批准号:
    21K17258
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
  • 批准号:
    499958-2016
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
    Engage Grants Program
Uhrf1 and the DNA damage response
Uhrf1 和 DNA 损伤反应
  • 批准号:
    311915
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
    Studentship Programs
Improvement of RNAi efficacy by blocking RNAi inhibitors
通过阻断 RNAi 抑制剂提高 RNAi 功效
  • 批准号:
    7109912
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
Development of an ICMT Supported Membrane Sensor
ICMT 支持的薄膜传感器的开发
  • 批准号:
    7037706
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
PhaseI/II Clinical Trial of hHB22.7 anti-CD22 Monoclonal Antibody for Lymphoma
hHB22.7抗CD22单克隆抗体治疗淋巴瘤I/II期临床试验
  • 批准号:
    7158852
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
Develop CEES-induced skin toxicity models and evaluate silibinin efficacy
开发 CEES 诱导的皮肤毒性模型并评估水飞蓟宾功效
  • 批准号:
    7235521
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
Mechanism of Formation of Polysulfane Anticancer Agents
聚硫烷抗癌剂的形成机理
  • 批准号:
    7059750
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
Islolated Hepatic Perfusion with Oxaliplatin
奥沙利铂离体肝灌注
  • 批准号:
    7056312
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents
α 叶酸受体介导的 GARFTase 抑制剂作为选择性抗肿瘤药物
  • 批准号:
    7187728
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了